Fierce Biotech1 min read
saveBiogen’s tau therapy drives bigger benefits in 2-year Alzheimer’s update
Biogen has linked its tau-targeting antisense oligonucleotide to a further slowing of clinical decline after two years, leading analysts to hail the strengthening of evidence supporting late-phase development.
comments(0)
5-min edit window · permanent after that